Peter Johnson On behalf of the CR UK Stratified Medicine Programme Molecular diagnosis of cancer: Making it a reality.

Slides:



Advertisements
Similar presentations
High Resolution studies
Advertisements

Cancer Registration and Health Service Regulation Dr Jenifer A E Smith.
Introduction to the unit and mixed methods approaches to research Kerry Hood.
You have recently set up a new disease service in your laboratory. What is the role of the UKGTN? Describe the process involved in submission & evaluation.
Diabetes and the Health Innovation Network Charles Gostling 19 September, 2013.
Senior Manager – Research Finance & Programmes
Local Improvement following National Clinical Audit The View from a National Clinical Audit Provider – the Health & Social Care Information Centre.
Information: to share or not to share? BCS HC 2012 Conference London 2 nd May Dame Fiona Caldicott.
Northern & Yorkshire Cancer Registry & Information Service NHS UKACR Conference 30 September How useful is the Cancer Waiting Times (CWT) dataset.
NPCA data submission and reporting
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
University of Pittsburgh Department of Biomedical Informatics Healthcare institutions have established local clinical data research repositories to enable.
The National Cancer Intelligence Network An overview Professor David Forman Professor of Cancer Epidemiology, University of Leeds NCIN – Lead for Information.
Cancer Research UK STRATIFIED MEDICINE PROGRAMME
Molecular Testing of lung cancer in routine practice
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
Kent & Medway Cancer Network Thames Cancer Registry Cancer Registration Dataset Pilot Nigel Brook.
Research-driven data standards CIMI 11 th April 2013.
Steps towards measuring Equity in Testing Dr Mark Kroese UKGTN Public Health Advisor UK Genetic Testing Network Conference 22 nd November 2012.
Expression profiling of peripheral blood cells for early detection of breast cancer Introduction Early detection of breast cancer is a key to successful.
National Confidential Inquiry into Suicide and Homicide by People with Mental Illness National Learning Disability Review Function Options Appraisal Report.
National Infrastructure Tina Yule Technical Assurance Co-ordinator 21 st Century Government Unit.
Visioning the Quality Performance Indicator (QPI) Reporting Programme Dr Bob Masterton Chair National Cancer Quality Steering Group.
Data Analysis Summary. Elephant in the room General Comments General understanding that informatics is integral in medical sequencing and other –omics.
100k Genomes Project In December 2012 the Prime Minister announced a programme of Whole Genome Sequencing as part of the UK Government’s Life Sciences.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Transforming Community Services Commissioning Information for Community Services Stakeholder Workshop 14 October 2009 Coleen Milligan – Project Manager.
The Health Roundtable Improving data collection rates, while improving quality Presenter: Sandra Avery Liverpool Innovation Poster Session HRT1215 – Innovation.
Chester Ellesmere Port & Neston Rural Making sure you get the healthcare you need West Cheshire CCG Strategy Dr Andy McAlavey Medical Director West Cheshire.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
Setting the scene 9 September 2010 Setting the scene Alan Willson 9 September 2010.
Data Quality Improvement This material was developed by Johns Hopkins University, funded by the Department of Health and Human Services, Office of the.
100k Genomes Project Programme of Whole Genome Sequencing, part of UK Life Sciences Strategy Aim to sequence 100,000 genomes from patients with cancer.
HTA Efficient Study Designs Peter Davidson Head of HTA at NETSCC.
UK Clinical Sarcoma Research. Changes in UK Appointment of Cancer Tsar Use of NICE to evaluate care pathways and technology/drugs Minimum datasets established.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks.
Facilitating tissue collection for translational research Jane Rogan Business Manager.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
What data are collected? How, and who by? Karen Graham and Barry Plewa.
NCIN Roadshow: Cancer Data NCIN - Cancer Data Roadshow Public Health England | 2015 Elsita Payne Head of Registration – East Midlands and North West Branches.
What does the cancer intelligence landscape look like now? Dr Mick Peake Clinical Lead, National Cancer Intelligence Network.
Specialist Palliative Care Data Professor Julia Verne Clinical Lead – National End of Life Care Intelligence Network (NEoLCIN) West Midlands Strategic.
CERVICAL CANCER SCREENING UPDATE Dr Keith Faulkner Quality Assurance Reference Centre NHS North East, Yorkshire and the Humber.
RARE SKIN TUMOURS IN THE SOUTH WEST J Weeks, V Poirier, J Verne, C Harling on behalf of the Skin Cancer Tumour Panel Objective NICE Improving Outcomes.
What data are collected? How, and who by?. It’s complicated… ONS data.
100,000 genomes project and haematological malignancy
Genomic Medicine Centre Overview
Choice – 6 Steps, 6 Actions, 6 Weeks
The 100,000 Genomes Project and the West of England Genomic Medicine Centre Brief update and overview provided by Catherine Carpenter-Clawson, Programme.
Clinical Trials Research Unit, University of Leeds, UK
100,000 Genomes Project & Mainstreaming Genomic Medicine
BOWEL CANCER SCREENING 11/7/18
Stratified medicine Dr Emily Shaw BM(Hons) MRCP(UK)
Genomic Medicine Centre Overview
Genomic Medicine Centre Overview
100,000 Genomes Project & Mainstreaming Genomic Medicine
Mainstreaming Genomic Medicine post 100,000 Genomes Project
The Genetic Basis for Cancer Treatment Decisions
100,000 Genomes Project & mainstreaming genomic medicine
Cancer WGS Analytical Pipeline Validation
Chris Wragg, Lead Cancer Scientist, SWGLH
Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib 
Genomic Medicine Centre Overview
100,000 Genomes Project & Mainstreaming Genomic Medicine
Scottish Cancer Registry and Intelligence Service (SCRIS)
Solving Unknown Primary cancER (SUPER)
Evaluating Community Link Working in Scotland: Learning from the ‘early adopters’ Jane Ford, NHS Health Scotland Themina Mohammed & Gordon Hunt, NSS Local.
Presentation transcript:

Peter Johnson On behalf of the CR UK Stratified Medicine Programme Molecular diagnosis of cancer: Making it a reality

The march of technology… Single genes Gene panels Whole exomes Whole genomes Plus expression profiling, copy number variation, epigenetics, miRNA profiles…

EGFR experience shows gradual test adoption even when funding is agreed Source: 12 months experience of EGFR testing in the UK, R. Butler, AstraZeneca et al, 2010

Background to the Programme SOMATIC MUTATION TESTING FOR PREDICTION OF TREATMENT RESPONSE IN PATIENTS WITH SOLID TUMOURS: – Already happening and demand predicted to increase – Funding not well established and access variable across the UK – Published data from quality assurance schemes suggest issues with the reproducibility and accuracy – Needs to work in formalin-fixed, paraffin embedded tissue – Needs to take account of multiple potential targets in each tumour – Little consensus on who to test, how to test, what to test or how to interpret and report the results

Service delivery component Research infrastructure The Stratified Medicine Programme pilot study combines service delivery and research components Central data repository (ECRiC)

Current gene list and technology

Stratified Medicine Programme Patient Dataset Derived from the core NHS Cancer Outcomes and Services Dataset (COSD): – New NHS information standard; mandation and stepwise implementation from January 2013 – Linked to modernisation of the cancer registries with creation of a unified National Cancer Registration Service in England – Sections for demographics, diagnosis, imaging, pathology, treatment and outcomes data – Aim for automated data collection and extraction as far as possible

8 Oct-12Nov-12Dec-12 Monthly recruitment Monthly samples sent * Monthly results returned Paired samples 63 (1.5%) 68 (1.5%) 69 (1.3%)

9

10

Results from the first 1000 cases Proportion of tumours with sequence variation by type

Data analysis: Breast cancer 260 sequence abnormalities detected in samples from 246 patients

Data analysis: Colorectal cancer

Data analysis: Lung cancer Pennell N A JOP 2012;8:34s-37s NOS = not otherwise specified

Findings from the Stratified Cancer Medicine programme General acceptability to patients: over 98% consent Key role of clinical teams for each tumour type Critical role of pathology department in managing tissue samples Impact of mass testing in technology hubs Value of QA system Highly variable sample quality, with impact on test failure rates Complexities of NHS IT. XML messaging protocols Automated data extraction not yet reliable 15

Challenges of obtaining the SM Programme patient dataset from routine clinical data Data reflects the patient pathway with a multitude of one-to- many relationships: repeating identifiers required in submitted data to ensure linkage in database Difficulty in sourcing some data items e.g. histopathology data, co-morbidity scoring, performance status Lack of inter-operability between information technology systems used in histopathology and other parts of the electronic patient record Use of Read codes and different versions of SNOMED Cross-border data issues: problems sourcing some demographic details

Future Priorities Improve completeness, linkage and standardization of submitted data Defining minimum sample requirements Optimising test turnaround times Moving towards routine commissioning of tests of proven utility Development of multiplex technology for parallel analysis of many genes Expansion of early phase therapy portfolio to exploit the molecular findings

Acknowledgements The patients who have consented to take part in the programme Lead investigators and teams at the clinical and technology hubs Stratified Medicine Programme team at CR-UK HQ Dr Jem Rashbass and team, National Cancer Registration Service Funding partners AstraZeneca and Pfizer